Chiasma, Inc. (NASDAQ:CHMA) Files An 8-K Results of Operations and Financial Condition
Item2.02. Results of Operations and Financial Condition.
On January9, 2017, Chiasma, Inc. (the Company) issued a press
release providing a year-end corporate update and preliminary
2017 outlook, which press release included the Companys
preliminary approximate cash, cash equivalents and marketable
securities as of December31, 2016. A copy of the press release is
being furnished as Exhibit 99.1 to this Report on Form8-K.
Item7.01.Other Events.
Reference is made to, and there is hereby incorporated by
reference into this Item7.01, the information set forth above
under Item 2.02. Results of Operations and Financial Condition.
Relating preliminary approximate cash, cash equivalents and
marketable securities as of December31, 2016.
The information in this Report on Form 8-K and Exhibit 99.1
attached hereto is intended to be furnished and shall not be
deemed filed for purposes of Section18 of the Securities Exchange
Act of 1934, as amended (the Exchange Act) or otherwise subject
to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as expressly set
forth by specific reference in such filing.
Item9.01. Financial Statements and Exhibits.
(d) Exhibits
|
|
|
|
| 99.1 |
Press release issued by Chiasma, Inc. dated January 9, 2017, furnished hereto. |
About Chiasma, Inc. (NASDAQ:CHMA)
Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company’s TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication. Chiasma, Inc. (NASDAQ:CHMA) Recent Trading Information
Chiasma, Inc. (NASDAQ:CHMA) closed its last trading session down -0.05 at 2.05 with 101,769 shares trading hands.
